ABSTRACT
The majority of cervical cancer cases are associated with persistent infection with one of the high-risk human papillomaviruses (HPV-HR). 2 The Papanicolaou (Pap) test is undoubtedly one of the biggest success stories in the history of preventive medicine, allowing early identification with subsequent treatment of the precancerous lesions of the cervix. The most commonly made abnormal diagnosis on a Pap test is "atypical squamous cells of uncertain significance" (ASCUS). 3 The recommended management of women with a diagnosis of ASCUS by Pap test is follow-up testing for HPV-HR to determine further management. 4 HPV-HR reflex testing may be concomitantly requested at the time of the Pap test for a resultant ASCUS diagnosis, or subsequently requested following the ASCUS diagnosis. When HPV-HR reflex testing is ordered concomitantly at the time of the Pap test, the cytopathologist may be aware of the HPV-HR reflex testing request at the time of the cytomorphologic interpretation of the Pap test. Currently, there are limited data in the literature that report the impact of a concomitant HPV-HR reflex testing request with the initial Pap test order on the cytomorphologic interpretation of the Pap test, and any subsequent effects on clinical practice and patient outcome. Peng and Wang 5 reported that a request for HPV-HR reflex testing "might have had a small, but insignificant" impact on the cytopathologists' interpretation of the ThinPrep Pap tests, but did not influence the subsequent clinical management of an ASCUS diagnosis. The most recent consensus guidelines for cervical cancer screening and management at the time of the Peng and Wang 5 study were from 2002 6 and 2001. 7 In over a decade since the publication of the similar previous study, the guidelines for primary cervical cancer screening and the management of abnormal cervical cytology have been updated. 4 These and the most recent American Cancer Society (ACS), American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP) consensus screening guidelines 8 for cervical cancer include new recommendations for cytology testing, HPV-HR testing, follow-up, and management, and incorporate more screening and management strategies based on HPV-HR testing. Furthermore, one HPV-HR test was approved by the US Food and Drug Administration in 2014 for primary cervical cancer screening. 9 The current indications for HPV-HR testing include (1) reflex testing of an ASCUS cytology result, (2) cotesting with cervical cytology and HPV-HR testing for cervical cancer screening in women 30 to 65 years and older, and (3) primary cervical cancer screening in women 25 years and older. 10 Because the indications for and the use of HPV-HR testing have increased, we revisited the question of whether concomitantly requested HPV-HR reflex testing affects the cytomorphologic interpretation of the Pap test. At our hospital, HPV-HR reflex testing for an ASCUS diagnosis can be concomitantly ordered by the clinician at the time of the Pap test order. Therefore, our laboratory receives Pap tests with (1) concomitantly ordered HPV-HR reflex testing for an ASCUS diagnosis; (2) cotesting, where both Pap test and HPV-HR testing is ordered simultaneously regardless of the cytologic diagnosis; and (3) an order for a Pap test only, without any accompanying HPV-HR testing request. Thus, we receive Pap tests with and without HPV-HR reflex testing requests, making it possible to study our hypothesis that knowledge of an HPV-HR reflex testing order for an ASCUS diagnosis received concomitantly with the Pap test order may influence the cytopathologist's interpretation of the Pap test to meet the criteria of an ASCUS diagnosis, such that the HPV-HR testing is performed.
Materials and Method

Case Identification
Consecutive cases of cervicovaginal ThinPrep Pap tests submitted to the cytology laboratory at the University of North Carolina Hospitals for a 6-month period (August 29, 2014 to February 25, 2015) were identified retrospectively. During this study period, 949 Pap tests were diagnosed and reported by six cytopathologists after an initial screening by cytotechnologists.
Data Collection
The following information was recorded from the cytopathology report and its corresponding clinical order, surgical pathology report for the concomitant biopsy (when applicable), and the electronic medical record: (1) patient age, (2) ordering provider clinic (obstetrics/general gynecology and family practice vs gynecologic oncology clinic), (3) cytopathologist's diagnosis of the Pap test, (4) years of experience of the cytopathologist, (5) nature of the HPV-HR testing order (if specified), (6) result of the HPV-HR testing (if available), and (7) follow-up colposcopy and result of concomitant biopsy (when applicable). Cytotechnologist interpretations were not included in this study. The cases were divided into three groups: (1) reflex, where concomitant HPV-HR reflex testing was requested with the Pap test for an ASCUS diagnosis; (2) cotesting, where HPV-HR was ordered with the Pap test irrespective of the cytologic diagnosis; and (3) not specified, where no HPV-HR testing order accompanied the Pap test. The "not specified" group was not further considered in this study because there was no clinical specification for HPV-HR testing that the cytopathologist could be aware of at the time of making the Pap test interpretation. The nature of the HPV-HR testing (reflex vs cotesting) was determined by the ordering clinician and was indicated on the clinical order/sample requisition form. The cytologic diagnoses considered included negative for intraepithelial lesion or malignancy (NILM), ASCUS, atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), and unsatisfactory (unsat). Glandular epithelial abnormalities were not included. No malignant cytologic diagnoses were made during the study period.
The standard information included in clinical orders for Pap tests at our hospital at the time of this study was patient age, ordering provider and clinic, collection information, nature of HPV testing (if designated), and Pap test source. This information was easily available on a one-page clinical order that was received with each Pap test slide at the time of slide review. HPV-HR results (if available for cotesting patients at the time of Pap test review) were not included in the paperwork accompanying the Pap test slide at the time of slide review but may have been available in the electronic medical record depending on the date of the HPV-HR result completion relative to the Pap test slide review date. In addition to the clinical order for the Pap test, the patient's past cytologic and surgical pathology diagnoses were also included in the paperwork accompanying the slide as a working draft, which may have been many pages long depending on the number of past pathologic diagnoses. As the study was retrospective, the cytopathologists were not aware of the study at the time of diagnosis. Therefore, it cannot be determined with certainty if the cytopathologists were aware of the nature of the HPV-HR testing order or, in the cotesting group, if the cytopathologists made themselves aware of the result of the HPV-HR test at the time of morphologic interpretation.
Data Analysis
The percentage of each cytologic diagnostic category was compared between the reflex and cotesting groups to determine if there was any difference in the morphologic interpretation of the Pap test when HPV-HR reflex testing was concomitantly ordered. A subset of the data was also analyzed by age stratification into two groups: women younger than 30 years old and women 30 years and older. Statistical analysis was performed using χ 2 test, Fisher exact test, and log binomial regression model of binary outcomes comparing groups. The ASCUS to squamous intraepithelial lesion (SIL) ratio and the HPV-HR positivity rate for ASCUS were also compared between the two groups as a measure of cytopathologist performance. The histologic diagnosis by subsequent colposcopy with tissue sampling (colposcopic biopsy and/or endocervical curettage) (if applicable) were compared between the two groups. The histologic diagnoses were considered in two groups: negative (no SIL identified) or positive (LSIL or HSIL). A subset analysis of the data was also performed to determine the effect of the level of cytopathologists' experience (0-5 years, 5-10 years, and >10 years). This research was approved by the University of North Carolina institutional review board, and requirement for informed consent was waived.
Results
A total of 949 ThinPrep Pap tests were interpreted by cytopathologists in our cytopathology laboratory during the 6-month study period. Concomitant HPV-HR reflex testing for an ASCUS diagnosis was ordered for 246 (25.9%) cases; 516 (54.4%) cases had HPV-HR cotesting ordered regardless of the cytomorphologic diagnosis, and for 187 (19.7%) cases, no HPV-HR testing request was received. The mean age of patients in the cotesting group was 42.7 years (standard deviation [SD] = 12.5), whereas patients in the reflex group were significantly younger with a mean age of 37.3 years (SD = 16.0) (P < .0001) ❚Table 1❚. Of the total 762 cases included in the study, 678 (89.0%) were collected in the obstetrics/general gynecology and family medicine clinics, and 80 (10.5%) were from the gynecologic oncology clinics. The clinic of collection was not available for four (0.5%) cases. Of the 516 cases in the cotesting group, 462 (89.5%) were collected in the obstetrics/general gynecology and family medicine clinics, 50 (9.7%) were from the gynecologic oncology clinics, and four were unknown (0.8%). Of the 246 cases in the reflex group, 216 (87.8%) were collected in the obstetrics/general gynecology and family medicine clinics, and 30 (12.2%) were from the gynecologic oncology clinics (Table 1 ). There was no significant difference in the clinic site of collection between the reflex and cotesting groups (P = .31; Table 1 ).
The proportion of ASCUS diagnoses in the reflex group (41.5%) was significantly higher than in the cotesting group (33.0%) with a χ 2 P value of .02 ❚Table 2❚. A Pap test in the reflex group was 26% more likely to be diagnosed as ASCUS than in the cotesting group (risk ratio 1.26 by log binomial regression model of binary outcomes comparing groups; P = .02) ❚Table 3❚. The percentage of NILM diagnoses was lower in the reflex group (21.5%) than in the cotesting group (25.6%), and the percentage of SIL cases was higher in the reflex group (18.3%) than in the cotesting group (15.9%); however, these differences did not reach statistical significance (P = .22 and P = .41, respectively; Table 2 ). The ASCUS to SIL ratio showed no statistical difference between the cotesting (2.07) and reflex (2.27) groups (P = .69). However, the ASCUS to NILM ratio was significantly higher in the reflex group (1.92) when compared to the cotesting group (1.29) (P = .05). These findings show that NILM diagnoses were decreased and ASCUS diagnoses were increased in the reflex group. As shown in Table 1 , the mean age of women in the reflex group (37.3 years) was significantly lower than in the cotesting group (42.7 years; P < .0001), which would be expected given the current screening recommendations. Because HPV infection is more prevalent in younger women, we analyzed a subset of the data by age. There were 192 women younger than 30 years old (25%, 73 in cotesting group and 119 in reflex group) and 568 women were 30 years and older (75%, 441 cotesting and 127 reflex group) (Supplementary Tables 1 and 2; all more likely to be diagnosed as ASCUS in the reflex group than in the cotesting group when adjusted for age (risk ratio 1.27 by log binomial regression model of binary outcomes comparing groups; P = .02; Table 3 ). By age stratification, a Pap test was 43% more likely to be diagnosed as ASCUS in the reflex group than in the cotesting group for women younger than 30 years of age (P = .06), but there was no significant difference for women 30 years and older (P = .51) (Supplementary Tables 3 and 4) .
Cytopathologist performance measures (ASCUS:SIL ratio and HPV-HR positivity for ASCUS) were compared between the two groups (Table 2) ❚Table 4❚. As discussed above, the ASCUS:SIL ratio was not statistically different between the two groups. Also, the HPV-positivity for ASCUS was not statistically different between the two groups (30.4% HPV-HR positive in the reflex group vs 25.6% HPV-HR positive in the cotesting group, P = .39; Table 4 ). To investigate any impact on clinical management and patient outcome, subsequent colposcopy with tissue sampling and histologic diagnoses were compared between the two groups ( Table 4) . Out of the combined 272 ASCUS diagnoses in the cotesting and reflex groups, cervical biopsies and/or endocervical curettage were performed in 54 (19.9%) patients: 34 in the cotesting group and 19 in the reflex group. One biopsy (from the reflex group) was eliminated from analysis because insufficient tissue was available for a definitive diagnosis. There were no malignant diagnoses by histology. No statistically significant difference was identified in histologic diagnoses of SIL between the cotesting and reflex groups (7.7% negative and 12.4% positive for SIL in the cotesting group vs 7.8% negative and 9.8% positive for SIL in the reflex group; P = .81), including the subset of ASCUS HPV-HR positive patients (16.3% negative and 34.9% positive for SIL in the cotesting group and 16.1% negative and 32.3% positive for SIL in the reflex group; P = .97; Table 4 ).
Finally, we performed a subset analysis of the data across experience levels of the cytopathologists. A Pap test was 67% more likely to be diagnosed as ASCUS by a cytopathologist with less than 5 years experience (P < .0001) and 27% more likely to be diagnosed ASCUS by a cytopathologist with 5 to 10 years' experience (P = .04) compared to a pathologist with more than 10 years experience by log binomial regression analysis ❚Table 5❚. However, there was no interaction between the reflex and cotesting groups and cytopathologist experience. Both the group and the cytopathologist experience independently affected the ASCUS diagnosis rate, and 
Discussion
Pathology is an interpretative diagnostic clinical field based on visual evaluation of patterns of tissue and cell alterations in disease as compared to normal tissues and cells. 11, 12 Pathology/cytopathology diagnosis is a highly complex heuristic process that requires integration of multiple clinical factors with visual patterns to make the most accurate interpretative diagnosis to explain these factors from a biological standpoint. 11, 12 Heuristic methods in medicine are susceptible to cognitive errors or biases (also known as failed heuristics and cognitive dispositions to respond), 13 and it is important for pathologists to be aware of these cognitive biases that may influence their diagnostic test interpretations. 14 Bias has been defined in the medical literature as "a systematic difference in an observed measurement, results, or conclusions from the true value" 15 due to "an unintentional inclination or preference that influences judgment." 16 Bias may affect the collection, analysis, interpretation, publication, or review of data. More than one hundred biases affecting medical decision making have been described, 14 and bias has been reported in the interpretation of histopathology 17, 18 and cytopathology. 5, 16, 19, 20 A small number of studies have reported biases in the interpretation of Pap tests by both cytotechnologists and cytopathologists. Biases in the interpretation of Pap tests have been reported due to knowledge of the HPV status by both cytotechnologists 19 and pathologists. 20 Moriarty et al 20 showed that knowledge of HPV-HR positivity biased the cytomorphologic Pap test interpretation to be more likely an abnormal result across both the general category of epithelial cell abnormalities and the descriptive categories of ASCUS, LSIL, and HSIL. Similarly, in the Tahoe study, 20 prior knowledge of a positive HPV-HR result significantly decreased the frequency of a NILM diagnosis (43.1% without knowledge of the HPV status vs 31.3% with knowledge of positive HPV status) and significantly increased the frequency of all epithelial cell abnormalities (56.9% without knowledge of the HPV status vs 68.7% with knowledge of the HPV status; P < .001 for both). The specific epithelial cell abnormalities in the biased vs the unbiased groups were 27.2% vs 24.0% for ASCUS, 22.4% vs 15.5% for LSIL, and 19.1% vs 17.4% for HSIL, respectively. 20 Similarly, Doxtader et al 19 showed that knowledge of HPV-HR positivity biased cytotechnologists' interpretation of Pap tests originally diagnosed as NILM to upgrade to ASCUS or worse. HPV-HR positive cases originally interpreted as NILM were significantly more likely to be upgraded to ASCUS when the HPV-positive status was known vs withheld (48% vs 36%, respectively, P = .001), while HPV-negative cases originally interpreted as NILM showed no difference in interpretation when the HPV-negative status was provided vs withheld (29% vs 29%, respectively, P = .93). They also showed a significant increase in referral to the pathologist for review when the HPV-positive status was known. However, their follow-up data showed no significant effect of the bias, and the prior knowledge of HPV positivity did not improve sensitivity for disease detection, although their study was not powered to determine if the bias would result in increased sensitivity for significant disease. 19 Also, their study did not look at whether the bias translated to cases signed out by cytopathologists after referral by cytotechnologists.
The most similar study to ours looking at the impact of HPV-HR reflex testing on the interpretation and management of ThinPrep Pap tests did not find a significant effect on cytopathologists' interpretations, although there © American Society for Clinical Pathology was a small but insignificant impact seen based on the ASC:SIL ratio (ASCUS:SIL ratio was 1.2 in the reflex testing group, 0.86 in their "no request group," and 0.62 in their cotesting group). 5 Also, they found no impact of a HPV-HR reflex testing request on the subsequent patient management or diagnosis of HSIL for an ASCUS diagnosis, although the number of cases with follow-up cervical biopsies was small. Given recent updates in the screening and management algorithms for Pap tests, which incorporate HPV-HR testing, studies of interpreter bias are increasingly relevant.
Our study suggests a bias toward an ASCUS diagnosis in the HPV-HR reflex testing group vs the cotesting group based on the significantly higher percentage of ASCUS diagnoses in the reflex group (41.5%) vs the cotesting group (33.0%), P = .02. This potential bias may be due to a combination of ascertainment and outcome bias. Ascertainment bias, also known as response bias, occurs when a physician's decision-making is preshaped by expectations or by what the physician specifically expects to find ("seeing what you expect to find"). 13 Outcome bias is the tendency to make a decision based on its known outcome, leading cognition to be based on what is wanted or known to happen rather than what is objective. 13 The prior knowledge of a reflex request for HPV-HR testing may bias the cytopathologist to render an ASCUS diagnosis based on a preconceived expectation of finding cytologic abnormalities in this group (ascertainment bias) and/or as a diagnosis that leads to the known outcome and reliance on a second test (HPV-HR testing) (outcome bias). Both ascertainment and outcome biases may affect cytopatholgists' interpretation of Pap tests such that preconceived expectations and/or stronger likelihood for a known outcome reduce thresholds of objectivity in making a cytologic diagnosis of ASCUS.
Other ascertainment biases in addition to knowledge of a HPV-HR reflex testing request that may affect Pap test interpretation include the specialty of the ordering physician and/or clinic of origin (gynecologic oncology vs general gynecology/obstetrics or family practice), and individual patient characteristics such as age, past medical history, prior histologic/cytologic diagnoses (especially of SIL), and HPV-HR positivity. We considered whether any patient characteristics may have been different between the reflex and cotesting groups that may have potentially contributed to bias. The patients in the reflex testing group were significantly younger than in the cotesting group, which is consistent with the current recommendations of cotesting in women 30 years and older. Given that the age would be expected to be lower in the reflex testing group based on national screening recommendations, our study populations have expected age ranges. The biology of HPV differs between younger women, where HPV is more prevalent and who tend to clear HPV infections, vs older women who do not clear HPV infections as well. It is therefore conceivable that age is a confounding factor or modifier for our finding of a higher percentage of ASCUS diagnoses in the reflex group. However, when adjusted for age, a Pap test was still 27% more likely to be diagnosed as ASCUS in the reflex group than in the cotesting group (P = .02), and younger patient age alone did not account for the higher percentage of ASCUS in the reflex group vs the cotesting group. We also analyzed the data by age stratification into two groups: women younger than 30 years of age and women 30 years and older. In women younger than 30 years of age, an ASCUS diagnosis was rendered more often in the reflex group compared to those in the cotesting group. However, no significant difference was noted in the percentage of ASCUS diagnoses between reflex and cotesting groups in women 30 years and older. In an age-stratified analysis, a Pap test was 43% more likely to be diagnosed as ASCUS in the reflex group compared to the cotesting group in women younger than 30 years of age; however, there was no difference for women 30 years and older. This absence of difference in women 30 years and older is of uncertain significance. Because cotesting is the current screening recommendation for women 30 years and older, the reflex testing number in , any difference in ASCUS diagnoses between the reflex and cotesting groups would be expected to be more easily identified in women younger than 30 years old, as the sample size is larger. As HPV is more prevalent in young women, this age group may also have more indeterminate cytologic findings such that any potential bias toward an ASCUS diagnosis is more easily identified. The percentage of patients with Pap tests collected from general gynecology/obstetrics and family practice vs gynecologic oncology clinics was not significantly different between the two groups, suggesting that the study population was similar between the two groups overall, but we did not look at the effect of individual patient's prior histories and/or histologic/cytologic diagnoses between the two groups. Because our study was retrospective, it is limited for a definitive interpretation of bias as being solely due to the nature of the HPV-HR testing request. Although the cytopathologists were not aware of the study at the time of diagnosis, we cannot know for certain whether the cytopathologists were aware of the nature of the HPV-HR testing order at the time of slide review. However, because this information was easily available on the accompanying one-page clinical order it can be reasonably assumed that this information was known by the cytopathologist and therefore an opportunity for bias of the interpretation of the Pap test exists. Similarly, it cannot be determined whether the cytopathologists were aware of any available HPV-HR result for the cotesting group at the time of morphologic interpretation, but the HPV-HR test result may have been available in the electronic medical record depending on the date of the HPV-HR result completion compared to the Pap test slide interpretation. It is conceivable that in the cotesting group, if the cytopathologist looked up the results of the HPV-HR test at the time of morphologic interpretation, that knowledge may potentially introduce an additional ascertainment bias.
Other potential contributory factors are individual patient characteristics and histories. Although past cytologic and surgical diagnoses were available, we cannot know the extent to which this information was factored into the morphologic diagnosis. In addition, due to the complexity of the heuristic process required for a morphologic interpretation that requires integration of multiple clinical factors with visual patterns, there may be other potential contributing factors that are not easily studied or appreciated. Although the cytotechnologists' interpretation may also be affected by the nature of the HPV-HR order, including an increase in referral to the pathologist if HPV-HR reflex testing is concomitantly requested, cytotechnologists' interpretations were not included in this study.
Also, an argument could be made that the cytopathologists' diagnoses could affect outcome without a preexisting HPV-HR reflex testing order based on current management protocols that recommend HPV-HR testing as the next step for an ASCUS diagnosis. However, the finding that the diagnoses in the HPV-HR reflex testing group were shifted to ASCUS from the NILM category (reflected by a significant difference in the ASCUS to NILM ratio between the groups), and a HPV-HR reflex testing request did not affect other epithelial abnormalities categories or the ASCUS to SIL ratio, suggests that the HPV-HR reflex testing request biased the Pap test from NILM interpretations towards ASCUS.
We also looked at whether the potential bias affected cytopathologist performance measures of ASCUS:SIL ratio and HPV-HR positivity rate for ASCUS 3 or clinical outcomes. Neither the ASCUS:SIL ratio nor the HPV-HR positivity rate for ASCUS were statistically different between the reflex and cotesting groups in our study. It should be noted that the HPV-HR positivity rate for ASCUS in our study group was overall low (25.6% for the cotesting group and 30.4% for the reflex group). Although the clinical follow-up data are limited due to small size and length of follow-up, there was also no statistically significant difference between histologic diagnoses of SIL between the two groups. This suggests that the potential bias was too small to affect cytopathologist performance or clinical outcomes, which are similar findings to those found by Peng and Wang, 5 who reported a higher ASCUS:SIL ratio in their reflex testing request group, but it did not reach statistical significance, and the HPV-HR positive rate was 49% in their reflex testing group, which conforms with the accepted benchmarks. 21 Peng and Wang 5 also similarly concluded that there was no significant impact on the management of ASCUS in their study based on cervical biopsies performed, histologic diagnoses, and results of HPV-HR testing among their groups. The differences between our study and the similar study done by Peng and Wang may be due to differences between the population groups and the data analysis. Peng and Wang had DOI: 10.1093/ajcp/aqy011 © American Society for Clinical Pathology a much larger reflex testing request group (58%, 2,659) and a much smaller cotesting group (1.8%, 82) compared to our study (25.9% [246] in the reflex group and 54.4% [516] in the cotesting group). This is most likely due to differences in current consensus guidelines for cervical cancer screening and management since publication of their study. Cotesting with HPV-HR testing and cytology was a preliminary recommendation for cervical cancer screening in women aged 30 and over in the 2002 guidelines, 6 and the more recent recommendation is for cotesting with both cytology and HPV-HR testing as primary screening in women 30 to 65 years and older. 8 Therefore, the greater number of women in the cotesting group in our study most likely reflects primary cervical cancer screening recommendations that followed the updated 2012 guidelines. In contrast, the cotesting group in the Peng and Wang 5 study (their group with HPV-HR testing performed regardless of the cytologic diagnosis) was mostly comprised of women having had a previous histocytologic discrepancy (eg, HSIL on cytology with negative biopsy), and the HPV positivity rate was very high in this group (77%). Therefore, the cotesting population in our study more likely reflects a screening population compared to their study, and is likely a better match with their "no request group" than with their cotesting group.
Finally, we considered the experience levels of the cytopathologists. Although a Pap test was more likely to be diagnosed as ASCUS by a less-experienced cytopathologist, there was no interaction between the reflex and cotesting groups and cytopathologist experience. Therefore, both the group and the cytopathologist experience independently affected the ASCUS diagnosis rate, and the cytopathologist experience alone did not account for the finding of a higher percentage of ASCUS diagnoses in the reflex group (Table 6) .
Cost comparison is an additional interesting consideration but is beyond the scope of this study.
In conclusion, our data suggest that a request for HPV-HR reflex testing may bias the cytopathologists' interpretation toward an ASCUS diagnosis and rely on a secondary HPV-HR test. This tendency is not affected by the level of pathologists' experience. It is important for pathologists to be aware of possible cognitive biases that may influence the objectivity of their diagnostic test interpretations.
